MONMOUTH JUNCTION, N.J., Feb. 11, 2021 /PRNewswire/ — DiamiR, a developer of innovative blood-based diagnostic tests for brain health and other diseases, today announced that it has received a notice of allowance from the United States Patent & Trademark Office (USPTO) for U.S. Patent Application No. 16/028,206 entitled “Methods of using miRNA from bodily fluids for diagnosis and monitoring of neurodevelopmental disorders.” The patent covers the use of methods developed by DiamiR based on targeted quantitative analysis of microRNAs enriched in the brain and other affected organs and detectable in blood plasma as biomarkers of Rett syndrome and other neurodevelopmental diseases.